Phase II study of cisplatin, pemetrexed plus bevacizumab for EGFR mutation negative or unknown stage III/IV non-small-cell lung cancer (non-squamous cell lung cancer)

Phase 2

• Conditions: EGFR mutation negative or unknown stage III/IV non-small-cell lung cancer (non-squamous cell carcinoma)

• Registration Number: JPRN-UMIN000003855
• Lead Sponsor: Departmnent of Thoracic Oncology Kanagawa Cancer Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-07-01
• Study Completion: 2015-07-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

Not provided

Exclusion Criteria

1)Massive pleural effusion 2)Massive pericardial effusion 3)Double cancer 4)Severe complications; myocardial infarction, unstable angina, heart failure, uncontrolled hypertension, and unconrolled diabetis mellitus, uncontrolled infection, uncontrolled mental disease, SVC syndrome 5)Hemoptysis(more than 2.5ml), continuous or treatment-required bloody sputum 6)Invasion to large vessels, cavity in tumor 7)Brain metastsis 8)Under anti-coagulation therapy 9)Bleeding 10)Nephrosis 11)Uncured wound 12)Digestive tract ulcer, diverticulosis 13)Bone marrow suppression 14)Lung fibrosis 15)Pregnancy 16)Other inappropriate cases

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
response rate

Secondary Outcome Measures

Name	Time	Method
overall survival, progression disease free survival, adverse event rate